Background: Despite advances in therapy of corneal ulcerative diseases in horses, a vast number of cases require surgical intervention, due to poor response to treatment. Topical application of serum has been used for many years, based on its anticollagenolytic properties and the presence of growth factors promoting corneal wound healing. However, although other blood derived products i.e. platelet rich plasma (PRP), plasma rich in growth factors (PRGF) have been widely used in equine orthopaedics and in human ophthalmology, no reports of the effects of these blood derived products exist in equine ophthalmology. Objectives: To determine in vitro effects of PRGF and PRP on equine corneal cells compared with serum. Study design: Prospective controlled cohort study. Methods: Blood from 35 healthy horses was used to produce serum, PRGF (Endoret â ), and PRP (E-PET TM ). Limbal-and stromal cells were isolated from healthy corneas of six horses and treated with 20% serum, 20% PRGF or 20% PRP. Proliferation rates and migration capacity were analysed in single cell cultures as well as co-culture systems. Results: Cell proliferation increased with PRP treatment, remained constant in PRGF treated cells, and declined upon serum treatment over a period of 48 h. Migration capacity was significantly enhanced with PRP treatment, compared with PRGF treatment. Intact leucocytes, mainly eosinophils, were only detected in PRP. Main limitations: Due to the study design use of autologous blood products on corneal cells was not possible.
Introduction
Corneal ulcerative diseases are of major concern to both veterinarians and the equine industry. Therapeutic regimens aim to prevent secondary bacterial and fungal infection and facilitate rapid reepithelialisation [1] . However, despite major advances in the treatment of ulcerative disease, equine ophthalmologists are still confronted with cases evincing poor healing capabilities. Autologous serum is commonly used due to its anticollagenolytic properties as well as the presence of growth factors in order to promote corneal wound healing and prevent corneal melting [2, 3] .
In recent years, various new blood derived products have been introduced (for review see [4] ), whereof platelet rich plasma (PRP) attracts substantial attention in the field of clinical research. A number of studies on the beneficial properties of PRP in equine orthopaedic disorders and wound healing exist [5] [6] [7] [8] . Recently, PRP and plasma rich in growth factors (PRGF) have been introduced in human ophthalmology, with promising results [9] [10] [11] [12] [13] . PRP has proven particularly beneficial in the treatment of nonhealing corneal ulcers, otherwise resistant to medical therapy [10] . PRGF has been found to stimulate scarless regeneration of the ocular surface in vitro [12] . The beneficial effects of PRGF and PRP on corneal wound healing have been attributed to the high amount of growth factors.
However, despite the many advantages these blood derived products evidently provide, they have not reached the attention of veterinary ophthalmology. Part of the reason may be the paucity of studies comparing PRGF and PRP to commonly used serum to promote corneal wound healing. Further reasons may include the large diversity in the amount of growth factors and cells contained in PRP, depending on the way it is produced [14] [15] [16] . Hessel and colleagues [14] compared four commercially available PRP systems for their use in horses and found differences in amounts of leucocytes, platelets as well as growth factors.
Based on the results of that study, the E-PET TM kit was chosen to produce PRP for our study. Furthermore, the Endoret â PRGF system was chosen due to the promising results in human ophthalmology [12] . The aim of this study was to determine the effects of equine PRP and PRGF on wound healing capabilities of equine corneal cells, compared with commonly used equine serum, and ultimately, to serve as a basis for subsequent in vivo studies in horses. We hypothesise that supplementation of equine PRGF and PRP to equine corneal cells result in superior proliferation and migration capacity of limbal cells than addition of equine serum.
Materials and methods

Preparation of blood derived products
Blood from 35 healthy horses (10 stallions, 15 mares and 10 geldings) was collected by venepuncture at the same time as samples taken during a routine health monitoring programme. Individual blood samples were processed according to the following three methods:
1 Serum: Five tubes, containing 9 mL whole blood, were collected from each horse. After spontaneous coagulation, tubes were centrifuged at 3600 rpm for 5 min and the complete supernatant fraction was collected aseptically using 10 mL syringes. 2 PRGF: For PRGF production, the Endoret â , KMU 15 US Disposable Kit a was used. Six sodium citrate tubes, containing 9 mL whole blood, were collected from each horse and immediately centrifuged at 1800 rpm for 8 min. Further processing was performed according to manufacturer's specifications. Briefly, after centrifugation the plasma column was divided into two fractions, fractions 1 and 2. Fraction 2, designated as PRGF, is determined to be 2 mL above the buffy coat, the remainder is regarded as fraction 1, and has variable volume. 3 PRP: PRP was produced using the E-PET TM kit b according to manufacturer 0 s instructions. In brief, 60 mL syringes were prefilled with 5 mL of ACD-A solution and 55 mL of blood from each horse were obtained in the same syringes. The syringes were injected into a collection bag, filled with 9 mL of capture-solution, before passing through a gravitational force driven filter. After back-flushing the filter with specialised harvest solution, 8-9 mL PRP were obtained from each horse.
The respective blood derivate samples from all 35 horses were pooled to minimise inter-individual variability. The pooled samples were aliquoted and stored at À20°C until use for further analysis.
Isolation and cultivation of equine primary corneal cell cultures
To obtain equine corneal limbal cells (ECLC) and stromal cells (ECSC), healthy corneas (n = 6) were collected from globes of horses euthanised for reasons unrelated to this study, under sterile conditions within 1 h post-mortem. Prior to euthanasia, a full ophthalmic examination was performed by a board certified ophthalmologist (B.N.) or 3rd year resident (J.R.) in veterinary ophthalmology, using slit lamp biomicroscopy (Kowa portable slit-lamp SL-14) . Fluorescein testing, mydriasis, and topical anaesthesia for tonometry were not applied to reduce the cytotoxic effects on corneal epithelium.
After enucleation, the whole cornea was removed under sterile conditions using a surgical microscope and ophthalmologic microsurgical instrumentation. Prior to keratectomy the cornea was rinsed with 0.5% iodine solution e . Following keratectomy, the cornea was segmented into four equivalent pieces and placed in 15 mL falcons containing full medium until further processing in cell culture under laboratory conditions. Full medium included Dulbecco's modified Eagle's medium (DMEM) f supplemented with 1% L-Glutamine f , 1% penicillin/streptomycin solution f and 10% heat-inactivated equine serum, which was produced during preparation of the three blood derivates, as described above. Corneal samples were washed twice with phosphate-buffered saline (PBS) f and digested in dispase enzyme (dispase type II, 2 mg/mL full medium) f solution over night at 4°C.
After enzyme digestion over night the pigmented limbal epithelium could easily be separated from the underlying stroma as described [17] . The pigmented cell sheets were incubated in 2 mL trypsin/EDTA solution (0.05%/0.02%) f for 5 min at 37°C to obtain single cell suspension of limbal cells. Trypsin was inactivated by adding full medium. After centrifugation (2000 rpm, 2 min), supernantant was removed and the remaining cell pellet from one complete corneal sample was dissolved in full medium and plated in two wells of a six well culture plate g . For stromal cell culture the anterior stroma was stripped from the posterior stroma and endothelium. In order to avoid inadvertant contamination with epithelial cells, only posterior stromal cells were used for stromal cell culture. Corneal stroma was sub-sectioned into small pieces and five to eight explants were placed in six-well-tissue culture plates containing full medium. After 3-5 days, cells began to migrate out of stromal explants and the explants were manually removed. ECLCs and ECSCs were cultured at 37°C in 5% CO 2 -95% air. Medium was exchanged three times per week.
Cells were also cultivated on glass slides to identify them immunohistochemically as described by Moriyama and colleagues [17] . Limbal epithelial cells stained positively for Cytokeratin 14 (1:100) Clone LL002 h and corneal stromal cells were determined using Vimentin (1:200) Clone V9 i staining. Cell culture experiments were performed in passage 4-8.
Proliferation assay
The impact of the three blood derived products on proliferation of ECLCs was evaluated using a MT Cell Viability Assay (RealTime-Glo TM ) j . ECLCs were plated at 7 9 10 3 cells/well in white 96-well plates k in full medium. The following day (=0 h), medium was substituted for a serum free medium containing 20% concentration of one of the three respective blood derived products. Cells were washed and incubated with RealTime-Glo TM substrate and enzyme j for 1 h at 37°C under 5% CO 2 atmosphere after 12, 24, 36, and 48 h. Luminescence signal was measured by a microplate reader (TECAN Infinite â 200PRO) l and proliferation rates were expressed as x-fold values compared with the control group treated with 1% serum arbitrary set to 1. After the measurement, cells were exposed to the respective treatment again.
Scratch assay
To analyse the influence of the blood derived products on the migration capacity of ECLCs, cells were seeded in 96-well plates g at a density of 2 9 10 4 cells/well in full medium. Upon 80% confluence, monolayers were disrupted with the tip of a 200 lL plastic pipette creating a punctate cell free area. Microphotographs of each well were taken immediately afterwards (=0 h) using a life cell imaging system (EVOS â ) k . Subsequently, cells were exposed to full medium containing 20% serum, PRGF or PRP, respectively. The control group was treated with full medium containing 1% serum. Scratches were photographed after 18, 30 and 42 h and sizes of cell free areas were measured using Image J software (freehand tool) m . Closure of the scratch was calculated as percentage in relation to cell free area at 0 h (arbitrary set to 100%).
Co-culture systems
To better mimic the in vivo situation, proliferation and migration experiments were also performed in co-culture systems, using transwell 96 permeable support systems (HTS Transwell â ) k with an insert pore size of 0.4 lm. ECLCs were seeded at the same cell concentrations used for single cell culture experiments into the receiver plates. Additionally, 7 9 10 3 ECSCs were seeded into the transwell inserts.
Haematological analyses of blood derived products
Serum and PRGF were examined by an impedance counter (V-sight â BC 2800 vet) n . Due to a strong haemolytic background, PRP was analysed using a laser flow cytometer (ADVIA â 2120i) o . Additionally, smears of centrifuged blood derived products were air-dried, fixed with methanol and stained with haematoxylin and eosin p .
Data analysis
A power calculation was performed using G*Power 3.1 and a sample size of six animals was determined. All further analyses were performed with IBM SPSS Statistics 22 software (SPSS, Chicago, IL) q . All experiments were performed in triplicates and repeated twice (i.e. duplicates). Mean values were calculated from triplicates resulting in 2 values (i.e. duplicates) per treatment and time point for each horse. These data passed the Kolmogorov-Smirnov Test for normality. Linear mixed models with REML method were used to assess the statistical significance of the impact of treatment and time. Differences between treatments and between points in time were analysed using Sidak 0 s alpha-correction as a post hoc procedure. A P≤0.05 was considered significant.
Results
Single cell culture
Cell proliferation: Proliferation rates of ECLCs were measured after 12, 24, 36, and 48 h exposure to the respective blood derived products. A time dependent effect was only seen in the PRP treatment group with increasing cell proliferation. Proliferation after 12 h was significantly lower compared with proliferation after 24, 36, and 48 h (Fig 1a) . Overall, no significant differences between the treatment groups were identified (Fig 1b) .
Scratch assay: Migration capacity of ECLCs was evaluated by a scratch assay, monitoring the closure of the cell free area over 42 h (Fig 2) . Time dependent effects on closure of cell free area were observed in all treatment groups (Fig 1c) . Significantly higher migration capacity was found after serum and PRP treatment compared with PRGF. However, only PRP treated cells showed superior migration capacity compared with cells in the control group (Fig 1d) . After 42 h, closure was most complete in the PRP treatment group (Figs 1c, 2i ).
Co-culture systems
Cell proliferation: A time-dependent effect with increasing cell proliferation was observed in the PRP group (Fig 3a) . Furthermore, proliferation decreased significantly after 48 h in serum treated cells (Fig 3a) . Overall, less cell proliferation was found after PRP treatment compared with serum and PRGF treated cells (Fig 3b) .
Scratch assay: A time dependent effect on closure of cell free area was only noticed in the PRP treatment group (Fig 3c) . Overall, migration capacity was significantly higher in the control group compared with serum and PRGF cultured cells (Fig 3d) . PRP treated cells showed significantly faster closure compared with serum and PRGF treatment (Fig 3d) . After 42 h, the mean remaining denuded area was smallest in cultures treated with PRP (Fig 3d) .
Haematological analyses of blood derived products: Serum and PRGF were analysed using an impedance counter, whereas PRP was analysed using a laser flow cytometer (Table 1 ). Subsequent to haematological measurements, smears of centrifuged blood derived products were performed (Fig 4) . No intact cells could be detected in serum and PRGF smears, however, high amounts of protein precipitates of various sizes, as well as cell remnants were seen. Some of these artefacts were falsely counted as cells (marked with * in Table 1 ) due to the size being identical to white blood cells. Besides the haemolytic background, protein precipitates and cell remnants, as well as a large number of intact cells were also noted in PRP samples. A remarkably high amount of intact eosinophilic granulocytes was detected (Fig 4b) .
Discussion
Use of blood derived products is a new method of treatment in the field of equine medicine [5] [6] [7] [8] . However, little is known about their effects on equine corneal cells. Therefore, PRGF and PRP were tested regarding their enhancing effects on wound healing processes compared with commonly used serum.
Successful wound healing is a complex interdependent mechanism, in which cell proliferation and migration play critical roles. Proliferation remained constant in the PRGF group during the investigation period of 48 h, and decreased upon serum treatment. In PRP treated cells, proliferation was significantly decreased at the first time point of measurement. A pro-migratory effect of PRP, which could be demonstrated in this study, might be a possible explanation. Due to constant remodelling of adhesion molecules during migration [18] , cells might have been washed off. Furthermore, adaption time of corneal cells to PRP media might have been prolonged, due to the presence of additional cellular particles in PRP. A proliferative effect of PRP has been demonstrated for various cell types, e.g. human subchondral mesenchymal progenitor cells [19] and human mesenchymal stem cells [20] as well as rabbit mesenchymal stem cells [21] . It has been shown that the enhanced proliferative effect of PRP compared with serum is even more distinct after prolonged treatment [20, 21] , which could also be observed in our experiments. Furthermore, the influence of the blood derived products on migration capacity, which is another important aspect for closure of corneal epithelial defects, was analysed. We found highest migration rates of ECLCs after PRP treatment. The potential of PRP to amplify migration capacity has been demonstrated in human mesenchymal stem cells, which was consistent with our observations in corneal cells. [20, 22] . Therefore, one may speculate that PRP is beneficial in corneal disorders requiring long-term therapies. Upon corneal damage, complete reepithelialisation and reorganisation of a structured stroma are essential in rebuilding intact function of the cornea. Epithelial-mesenchymal interactions occurring in vivo, have beneficial effects during wound healing process [23] . To better mimic the natural morphology of corneal tissue, co culture systems were applied in vitro. Therefore ECSCs were cultivated together with ECLCs. Experiments in coculture systems revealed consistent results to those in single cell culture. An enhancing effect of substituted corneal stromal cells could not be determined. The observed effect was attributed to the influence of PRP on limbal cells rather than stromal cells. The three pooled blood derived products were analysed haematologically. Haematology of blood samples of individual horses was not performed, since variabilities between horses of various age-groups and genders were expected and counteracted by pooling the respective blood derivates [24] . A noteworthy aspect was high amounts of eosinophils, which were observed in PRP. Interestingly, these cells remained intact after freezing at À20°C. It is known that equine PRP produced with the E-PET TM system contains leucocytes, therefore the product is also called L-PRP [25] . Eosinophils are especially enriched compared with the base line [14] . Eosinophils are well-investigated in numerous diseases, such as allergic disorders [26] , parasitic diseases [27] and pulmonary diseases [28] . They are a source of various cytokines and growth factors for example vascular endothelial growth factor (VEGF), platelet derived growth factor (PDGF), transforming growth factor-b (TGF-b), Interleukins (IL-6, IL-8), fibroblast growth factor-2 (FGF-2) and hepatocyte growth factor (HGF) [29] [30] [31] and may therefore act as pro-inflammatory as well as anti-inflammatory mediators [31] . It has been shown that HGF may prevent corneal haze development by supressing conversion of corneal fibroblasts into myofibroblasts [32] . Based on this knowledge it can be assumed, that intact eosinophils occurring in the E-PET TM PRP system may promote corneal wound healing, due to their capacity to release important cytokines and growth factors in the special context of corneal wound healing.
Our results revealed that proliferation remained constant in the PRGF group and decreased upon serum treatment. Moreover, migration capacity was enhanced in serum treated cells compared with PRGF treatment. However, there have been contradicting results in past research, some of which revealed PRGF as the most potent blood derived product [12, 33] . Differences in study designs regarding use of control groups may be a contributing factor to the significant differences in results [13] . Furthermore, variable production processes for PRGF and PRP may significantly influence the outcome of in vitro studies and clinical trials [19] . The lack of a standardised PRP preparation protocol for clinical application has contributed to a disparity in clinical efficacy of PRP [15, 16, 19] . Therefore, consistent nomenclatures as well as defined cellular and molecular properties of PRP used in research and clinical application are of major importance [34] . An appropriate selection of commercially available PRP preparation kits for use in horses is therefore required.
In summary, PRP produced with the E-PET TM system showed promising results by enhancing proliferative capacity, as well as migratory capacity after prolonged treatment of equine corneal cells in vitro. Consequently, PRP should further be tested in vivo to analyse its full potential for clinical ophthalmological use. 
